Chronopharmacology of oxacalcitriol in 5/6 nephrectomized rats

Life Sciences

Volumn 75, Issue 7, 2004, Pages 809-822

  Tsuruoka, Shuichi ^a   Nishiki, Kenta ^a   Wakaumi, Michi ^a   Yamamoto, Hisahi ^a   Ando, Hitoshi ^a   Ning, Wang ^a   Fujimura, Akio ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

22 oxacalcitriol; Chronotherapy; Hypercalcemia; Renal osteodystrophy

Indexed keywords

ALBUMIN; CALCIUM; DEOXYPYRIDINOLINE; OXACALCITRIOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CHRONOPHARMACOLOGY; CONTROLLED STUDY; DISEASE SEVERITY; EVALUATION; HYPERCALCEMIA; HYPERPHOSPHATEMIA; LIGHT DARK CYCLE; MALE; NEPHRECTOMY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; RAT;

AMINO ACIDS; ANIMALS; BONE DENSITY; CALCITRIOL; CALCIUM; CHRONOTHERAPY; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMUR; HYPERCALCEMIA; MALE; NEPHRECTOMY; PARATHYROID HORMONE; PHOSPHATES; RATS; RATS, WISTAR;

ANIMALIA;

EID: 2942525393     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2004.01.020     Document Type: Article

References (27)

1. Balsalobre A. Clock genes in mammalian peripheral tissues. Cell Tissue Res. 309:2002;193-199
2. Brown A.J., Finch J., Grieff M., Ritter C., Kubodera N., Nishii Y., Slatopolsky E. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology. 133:1993;1158-1164
3. Calvo M.S., Eastell R., Offord K.P., Bergstralh E.J., Burritt M.F. Circadian variation in ionized calcium and intact parathyroid hormone: evidence for sex differences in calcium homeostasis. J Clin Endocrinol Metab. 72:1991;69-76
4. Connerty H., Briggs A. Determination of serum calcium by means of orthocresolphtalein complexone. Am J Clin Pathol. 45:1966;290-296
5. Drewes P. Direct colorimetric determination of phosphorus in serum and urine. Clin Chim Acta. 39:1972;81-88
6. Farach-Carson M.C., Abe J., Nishii Y., Khoury R., Wright G.C., Norman A.W. 22-Oxacalcitriol: dissection of 1, 25(OH)2D3 receptor-mediated and Ca2+ entry-stimulating pathways. Am J Physiol. 265:1993;F705-F711
7. Ishigai M., Asoh Y., Kumaki K. Determination of 22-oxacalcitriol, a new analog of 1alpha, 25-dihydroxyvitamin D3, in human serum by liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl. 706:1998;261-267
8. Kobayashi T., Tsugawa N., Okano T., Masuda S., Takeuchi A., Kubodera N., Nishii Y. The binding properties, with blood proteins, and tissue distribution of 22-oxa-1 alpha, 25-dihydroxyvitamin D3, a noncalcemic analogue of 1 alpha, 25-dihydroxyvitamin D3, in rats. J Biochem (Tokyo). 115:1994;373-380
9. Kubrusly M., Gagne E.R., Urena P., Hanrotel C., Chabanis S., Lacour B., Drueke T.B. Effect of 22-oxa-calcitriol on calcium metabolism in rats with severe secondary hyperparathyroidism. Kidney Int. 44:1993;551-556
10. Mrosovsky N., Salmon P. A behavioural method for accelerating re-entrainment of rhythms to new dark-light cycles. Nature (Lond). 330:1987;372-373
11. Nishiki K., Tsuruoka S., Wakaumi M., Yamamoto H., Koyama A., Fujimura A. Dosing time-dependent variation in the hypocalcemic effect of calcitonin in rat. Eur J Pharmacol. 460:2003;171-175
12. Parfitt A.M. Use of calciferol and its metabolites and analogues in osteoporosis. Current Status, Drugs. 36:1988;513-520
13. Seyedin S., Kung V., Danilhoff Y., Hesley R., Gomez B., Nielsen L., Rosen H., Zuk R. Immunoassay for urinary pyridinoline: The new marker of bone resorption. J Bone Miner Metab. 8:1993;635-642
14. Shen V., Birchman R., Xu R., Lindsay R., Dempster D.W. Short-term changes in histomorphometric and biochemical turnover markers and bone mineral density in estrogen-and/or dietary calcium-deficient rats. Bone. 16:1995;149-156
15. Shinoda H., Seto H. Diurnal rhythms in calcium and phosphate metabolism in rodents and their relations to lighting and feeding schedules. Miner Electrolyte Metab. 11:1985;158-166
16. Shinoda H., Stern P.H. Diurnal rhythms in Ca transfer into bone, Ca release from bone, and bone resorbing activity in serum of rats. Am J Physiol. 262:1992;R235-R240
17. Sugimoto K., Tsuruoka S., Fujimura A. Renal protective effect of YM598, a selective endothelin ET(A) receptor antagonist, against diabetic nephropathy in OLETF rats. Eur J Pharmacol. 450:2002;183
18. Sugimoto K., Tsuruoka S., Matsushita K., Fujimura A. Effects of candesartan cilexetil on oxidative state and renal function in 5/6 nephrectomized rats. J Hum Hypertens. 13(Suppl 1):1999;S63-S70. (discussion S81)
19. Takahashi J., Zatz M. Regulation of circadian rhythmicity. Science (Wash). 217:1982;1104-1111
20. Takamure M., Murakami N., Takahashi K., Kuroda H., Etoh T. Rapid re-entrainment of the circadian clock itself, but not the measurrable activity rhythms to a new light-dark cycles in the rat. Physiol and Behaviour. 50:1991;443-449
21. Tsuruoka S., Nishiki K., Sugimoto K., Fujimura A. Chronotherapy with active vitamin D3 in aged stroke-prone spontaneously hypertensive rats, a model of osteoporosis. Eur J Pharmacol. 428:2001;287-293
22. Tsuruoka S., Nishiki K., Sugimoto K., Fujimura A. Time of day improves efficacy and reduces adverse reactions of vitamin D3 in 5/6 nephrectomized rat. Life Sci. 71:2002;1809-1820
23. Tsuruoka S., Sugimoto K., Fujimura A. Contribution of the diet to the dosing time-dependent change of vitamin D3 induced hypercalcemia in rats. Life Sci. 68:2000;579-589
24. Tsuruoka S., Sugimoto K., Ohmori M., Kawaguchi A., Saito T., Fujimura A. Chronotherapy of high-dose 1, 25-dihydroxyvitamin D3 in hemodialysis patients with secondary hyperparathyroidism: a single-dose study. Clin Pharmacol Ther. 66:1999;609-616
25. Tsuruoka S., Wakaumi M., Sugimoto K., Saito T., Fujimura A. Chronotherapy of high-dose active vitamin D3 in haemodialysis patients with secondary hyperparathyroidsm: a repeated dosing study. Br J Clin Pharmacol. 55:2003;531-537
26. Turek F. Circadian neural rhythms in mammals. Ann Rev Physiol. 47:1985;49-64
27. Yamauchi H., Kobayashi E., Sugimoto K., Tsuruoka S., Yabana M., Ishii M., Fujimura A. Time-dependent cyclosporine A-induced nephrotoxicity in rats. Clin Exp Pharmacol Physiol. 25:1998;435-440